Reijo Laaksonen MD, PhD

Dr. Laaksonen is a clinical pharmacologist with a key interest in cardiovascular prevention. He spent six years at the Clinical Research Institute of Montreal and Université Libre de Bruxelles as a post-doctoral fellow and visiting scientist prior to joining Zora Biosciences Oy as CMO. He is a co-inventor of more than 20 biomarker patents and has published over 150 scientific articles. Dr. Laaksonen has also served Research Professor at Tampere University and Medical Director of the Finnish Clinical Biobank Tampere. Currently, he holds also a position as Research Director at Tampere University. He was recently awarded 20 million € funding by the EU for the “CoroPrevention” project to evaluate the efficacy of personalized prevention in high-risk Coronary Heart Disease patients.CoroPrevention project associates closely with earlier successful EU projects AtheroRemo, RiskyCAD, and AtheroFlux.